SNCG在卵巢癌中的表达及其临床意义

doi:10.3969/j.issn.1000-8535.2021.05.001

摘要/Abstract

摘要： 目的探讨SNCG蛋白在卵巢癌组织中的表达情况及临床意义,明确SNCG在人卵巢癌中的表达情况及其恶性程度的关系,为临床卵巢癌的诊断、治疗及预后提供理论依据。方法收集2010年1月—2015年1月石河子大学医学院第一附属医院收治的具有完整临床病理资料和石蜡切片的119例卵巢癌以及50例正常卵巢患者,用免疫组化方法检测组织中SNCG的表达情况,并分析SNCG的表达与卵巢癌患者临床病理特征及预后的关系。结果 SNCG在卵巢癌组织中的表达高于正常卵巢组织(χ²=73.575,P＜0.001);SNCG的表达与卵巢癌患者的肿瘤分期、分化程度、淋巴结转移、达到满意减瘤术、CA125以及HE4水平相关,差异均有统计学意义(P＜0.05);与卵巢癌肿瘤的原发部位、腹水、复发及化疗耐药无关,差异无统计学意义(P＞0.05);SNCG的过表达与HGSOC患者的PFS、OS相关,差异有统计学意义(P＜0.05);多变量Cox比例风险模型分析显示SNCG是HGSOC患者的独立预后因素,与PFS(HR=2.107,95%CI:1.014～3.795,P=0.034)、OS(HR=1.238,95%CI:0.716～1.928,P=0.047)相关。结论 SNCG在卵巢癌中高表达,与患者肿瘤分期、分化程度、淋巴结转移、达到满意减瘤术、CA125以及HE4水平有关,与卵巢癌患者的复发与化疗耐药无关,SNCG蛋白的过表达可作为HGSOC患者的独立预后因素,指导临床诊治。

关键词: SNCG, 卵巢癌, 临床病理特征, 预后

Abstract: Objective To detect the expression of SNCG in ovarian cancer tissue and its clinical significance, to clarify the relationship between the expression of SNCG in human ovarian cancer and the degree of malignancy, so as to provide theoretical basis for the diagnosis, treatment and prognosis of clinical ovarian cancer. Methods From January 2010 to January 2015 in First Affiliated Hospital of Medical College of Shihezi University,119 patients with ovarian cancer and 50 patients with normal ovarian which had complete clinical data and paraffin section were selected. Immunohistochemical method was used to detect ovarian SNCG expression, and the expression of SNCG relationship with clinical pathological characteristics and prognosis of patients with ovarian cancer was analyzed. Results The expression of SNCG in ovarian cancer tissue was significantly higher than that in normal ovarian tissue (χ²=73.575,P＜0.001). SNCG expression was correlated with tumor stage, degree of differentiation, lymph node metastasis, satisfying tumor reduction, CA125 and HE4 levels in ovarian cancer patients, and the differences were statistically significant (P＜0.05). It was not correlated with the tumor primary site, ascites, recurrence of ovarian tumor and chemotherapy resistance, and the differences were not statistically significant (P＞0.05).The overexpression of SNCG was correlated with PFS and OS in HGSOC patients, and the differences were statistically significant (P＜0.05). Analysis of multivariate Cox proportional risk model showed that SNCG was an independent prognostic factor in patients with HGSOC, related to PFS (HR=2.107,95%CI: 1.014-3.795,P=0.034) and OS (HR=1.238,95%CI: 0.716-1.928,P=0.047). Conclusion The high expression of SNCG in ovarian cancer is related to tumor stage, degree of differentiation, lymph node metastasis, satisfying tumor reduction, CA125 and HE4 expressions, but it is not related to the recurrence of ovarian cancer or chemotherapy resistance. The overexpression of SNCG protein can be used as an independent prognostic factor in patients with HGSOC for clinical diagnosis and treatment guidance.

Key words: SNCG, ovarian cancer, clinicopathological features, prognosis

肖驰, 周雪, 徐丹, 杨美英, 费晶, 巩平. SNCG在卵巢癌中的表达及其临床意义[J]. 广州医药, 2021, 52(5): 1-7.

XIAO Chi, ZHOU Xue, XU Dan, YANG Meiying, FEI Jing, GONG Ping. The expression of SNCG and clinical significance in ovarian cancer[J]. Guangzhou Medical Journal, 2021, 52(5): 1-7.

参考文献

[1] CHEN W, ZHENG R, BAADE P D, et al. Cancer statistics in China,2015[J].CA Cancer J Clin,2016,66(2):115-132.
[2] FERLAY J, SOERJOMATARAM I, DIKSHIT R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012[J].Int J Cancer,2015,136(5):E359-386.
[3] GAMARRA-LUQUES C D, GOYENECHE A A, HAPON M B, et al. Mifepristone prevents repopulation of ovarian cancer cells escaping cisplatin-paclitaxel therapy[J]. BMC Cancer,2012,12:200.
[4] MAKARA P, TROPÉ C G, TUMMERS P, et al. Advanced ovarian cancer:primary or interval debulking? Five categories of patients in view of the results of randomized trials and tumor biology: primary debulking surgery and interval debulking surgery for advanced ovarian cancer[J]. Oncologist,2016,21(6):745-754.
[5] TORRE L A, TRABERT B, DESANTIS C E. Ovarian cancer statistics,2018[J].CA Cancer J Clin,2018,68(4):284-296.
[6] KORKMAZ T, SEBER S, BASARAN G. Review of the current role of targeted therapies as maintenance therapies in first and second line treatment of epithelial ovarian cancer; in the light of completed trials[J]. Crit Rev Oncol Hematol,2016(98):180-188.
[7] KOBAL B, NOVENTA M, CVJETUCANIN B, et al. Primary debulking surgery versus primary neoadjuvant chemotherapy for high grade advanced stage ovarian cancer: comparison of survivals[J].Radiol Oncol,2018, 52(3):307-319.
[8] HOWLADER N A, KRAPCHO M, MILLER D, et al. SEER cancer statistics review, 1975-2013[J]. Natl Cancer Inst Res Rep, 2016,17(4):927-943.
[9] TASTEKIN D, KARGIN S, KARABULUT M, et al. Synuclein-gamma predicts poor clinical outcome in esophageal cancer patients[J].Tumour Biol, 2014, 35 (12):11871-11877.
[10] LIU C, SHI B, HAO C, et al. Urine gamma-synuclein as a biomarker for the diagnosis of bladder cancer[J].Oncotarget, 2016, 7 (28):43432-43441.
[11] DUYCKAERTS C. Neurodegenerative lesions: seeding and spreading[J].Rev Neurol,2013,169(10):825-833.
[12] BUCHMAN V L,HUNTER H J,PINÕN L G,et al. Persyn, a member of the synuclein family, has a distinctpattern of expression in the developing nervous system[J]. J Neurosci,1998,18(22):9335-9341.
[13] SURGUCHOV A, PALAZZO R E,SURGUCHEVA I. Gamma synuclein: subcellular localization in neuronal and non-neuronal cells and effect on signal transduction[J]. Cell Motil and the Cytoskelet,2001,49(4):218-228.
[14] LAVEDAN C, LEROY E, DEHEJIA A, et al. Identification, localization and characterization of thehuman γ-synuclein gene[J]. Hum Genet,1998,103(1):106-112.
[15] SINGH V K, JIA Z. Targeting synuclein-γ to counteract drug resistance in cancer[J]. Expert Opin Ther Targets,2008,12(1):59-68.
[16] MA Z, NIU J, SUN E, et al. Gamma-synuclein binds to AKT and promotes cancer cell survival and proliferation[J]. Tumour Biol,2016,37(11):14999-15005.
[17] MHAWECH-FAUCEGLIA P, WANG D, SYRIAC S, et al. Synuclein-γ (SNCG) protein expression is associated with poor outcome in endometrial adenocarcinoma[J]. Gynecol Oncol,2012,124(1):148-152.
[18] SHAO T, SONG P, HUA H, et al. Gamma synuclein is a novel Twist1 target that promotes TGF-β-induced cancer cell migration and invasion[J]. Cell Death Dis,2018,9(6):625.
[19] 党荣良,沈福海,夏庆安,等.卵巢癌组织中γ-synuclein蛋白的表达意义[J].现代预防医学,2009,36(18):3551-3553.
[20] STROHL A, MORI K, AKERS S, et al. Synuclein-γ (SNCG) expression in ovarian cancer is associated with high-risk clinicopathologic disease[J]. J Ovarian Res,2016,9(1):75.
[21] NEELAKANTAN D, DOGRA S, DEVAPATLA B, et al. Multifunctional APJ pathway promotes ovarian cancer progression and metastasis[J]. Mol Cancer Res,2019,17(6):1378-1390.
[22] CARNERO A, BLANCO-APARICIO C, RENNERS O, et al. The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications[J]. Curr Cancer Drug Targets, 2008,8(3):187-198.
[23] MABUCHI S, KURODA H, TAKAHASHI R, et al. The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer[J]. Gynecol Oncol,2015,137(1):173-179.
[24] GASPARRI M L, BARDHI E, RUSCITO I, et al. PI3K/AKT/mTOR pathway in ovarian cancer treatment: are we on the right track?[J]. Geburtshilfe Frauenheilkd, 2017,77(10):1095-1103.[25] ZHANG J, LIU X H, LI C, et al. SNCG promotes the progression and metastasis of high-grade serous ovarian cancer via targeting the PI3K/AKT signaling pathway [J]. J Exp Clin Cancer Res,2020,39(1):79.
[26] WINDER A D, MANIAR K P, WEI J J, et al. Synuclein-γ in uterine serous carcinoma impacts survival: an NRG oncology/gynecologic oncology group study.[J].Cancer,2017,123(7):1144-1155.
[27] LIANG W, MIAO S, ZHANG B, et al. Synuclein-γ protects Akt and mTOR and renders tumor resistance to Hsp90 disruption[J]. Oncogene,2015,34(18):2398-405.
[28] SHAO Y, WANG B, SHI D, et al. Synuclein gamma protects HER2 and renders resistance to Hsp90 disruption[J]. Mol Oncol,2014,8(8):1521-1531.
[29] LIU C, MA H, QU L, et al. Elevated serum synuclein-gamma in patients with gastrointestinal and esophageal carcinomas 2012[J].Hepatogastroenterology,2012,59(119):2222-2227.
[30] LIU C, QU L, SHOU C. Role and characterization of synuclein-γ unconventional protein secretion in cancer cells[J]. Methods Mol Biol,2016(1459):215-227.
[31] LHEUREUX S, GOURLEY C, VERGOTE I, et al. Epithelial ovarian cancer[J]. Lancet,2019,393(10177):1240-1253.
[32] EDIRIWEERA M K, TENNEKOON K H, SAMARAKONON S R. Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer: biological and therapeutic significance[J]. Semin Cancer Biol,2019(59):147-160.
[33] WU X, LUO Q, ZHAO P, et al. MGMT-activated DUB3 stabilizes MCL1 and drives chemoresistance in ovarian cancer[J]. Proc Natl Acad Sci U S A,2019,116(8):2961-2966.
[34] ZHANG H, KOUADIO A, CARTLEDGE D, et al. Role of gamma-synuclein in microtubule regulation[J]. Exp Cell Res,2011,317(10):1330-1339.
[35] MIAO S Y,WU K J,ZHANG B et al. Synuclein-γ compromises spindle assembly checkpoint and renders resistance to antimicrotubule drugs[J].Mol Cancer Ther, 2014, 13(3): 699-713.